Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.60 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5011277 | 0.98 | MEN1 (0.70) | MEN1KMT2AOPRD1OPRM1OPRK1 | |
| SCHEMBL5106757 | 0.94 | CYP2D6 (0.61) | MEN1KMT2AOPRD1OPRM1OPRK1 | |
| SCHEMBL16225913 | 0.93 | MEN1 (0.61) | MEN1KMT2AOPRD1OPRM1OPRK1 | |
| SCHEMBL4135481 | 0.87 | MEN1 (0.66) | MEN1KMT2AOPRD1OPRM1OPRK1 | |
| SCHEMBL2794662 | 0.85 | MEN1 (1.00) | MEN1KMT2AOPRD1OPRM1CYP2D6 | |
| SCHEMBL219432 | 0.85 | MEN1 (1.00) | MEN1KMT2AOPRD1OPRM1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7006476 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1OPRM1CYP2D6 | |
| SCHEMBL27485345 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1OPRM1CYP2D6 | |
| Hydrochloric Acid SCHEMBL11456225 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1OPRM1CYP2D6 | |
| Piperazine SCHEMBL28229145 | 0.83 | MEN1 (0.96) | MEN1KMT2AOPRD1OPRM1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387566-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-05-07 | — | — | EP | claimed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2387566-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2011-11-23 | — | — | EP | claimed |
| US-20110253932-A1 | OPTICAL FUNCTIONAL FILM, RETARDATION FILM, COMPOSITION FOR FORMING OPTICAL FUNCTIONAL LAYER AND PRODUCING METHOD OF OPTICAL FUNCTIONAL FILM | DAI NIPPON PRINTING CO., LTD. (JP) | 2011-10-20 | — | — | US | claimed |
| WO-2010081861-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2010-07-22 | — | — | WO | claimed |
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2752407-B1 | Crystalline rosuvastatin calcium trihydrate | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2015-09-23 | — | — | EP | disclosed |
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-1020443-B1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | AZWELL INC (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6172228-B1 | Process for producing piperazinesulfonamide derivatives and salts thereof | AZWELL INC. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1020443-A1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | Azwell Inc. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5703071-A | Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0546102-B1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | UPJOHN CO (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5594144-A | TREATING CEREBROVASCULAR AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0546102-A1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES. | UPJOHN CO (US) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992004338-A1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | THE UPJOHN COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | MEN1 2625/4885KMT2A 843/4885OPRD1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.